SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:98d735e9-661d-4620-a37a-2f4962abeec4"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:98d735e9-661d-4620-a37a-2f4962abeec4" > Patents, Morality a...

Patents, Morality and Biomedical Innovation in Europe : Historical overview, current debates on stem cells, gene editing and AI, and de lege ferenda reflections

Nordberg, Ana (författare)
Lund University,Lunds universitet,Juridiska institutionen,Juridiska fakulteten,Health Law,Forskargrupper vid Lunds universitet,Mänskliga rättigheter,Affärsrättsligt centrum vid Lunds Universitet, ACLU,Department of Law,Faculty of Law,Lund University Research Groups,Human Rights Law,Lund University Centre for Business Law (Swedish abbr: ACLU)
Gervais, Daniel (redaktör/utgivare)
 (creator_code:org_t)
2020
2020
Engelska 24 s.
Ingår i: Fairness, Morality and Ordre Public in Intellectual Property. - 978 1 83910 436 7 - 978 1 83910 437 4 ; , s. 243-267
  • Bokkapitel (refereegranskat)
Abstract Ämnesord
Stäng  
  • This paper discusses the existence and scope of the morality exception from patentability, in Article 53 (a) of the European Patent Convention. The analysis will look into the history of the provision, debate its rational and interpretation by reference to three examples of technology areas: stem cell research; gene editing and AI/big data analytics.Bioscience innovation has always generated heated ethical debates in society. The patent system is not immune to such discussions. The European Patent convention contains a morality and ‘ordre public’ exception in Article 53 (a) EPC, preventing patentability on grounds of lack of ethical compliance of the invention with prevailing standards. Many other jurisdictions have similar provisions or somehow impose restrictions on patentability based on similar ratio legis. The topic is further regulated in Article 6 of the Biotechnology Directive (which is also adopted in the EPC implementing rules). The ratio legis of this norm, the standards for its applicability and legitimacy to develop them are far from clear or consensual. Innovation in cutting edge biosciences implies always a certain level of uncertainty concerning future technological possibilities. The same can be said in regards to any legislative attempt to regulate such technologies. The Biotechnology Directive was enacted in 1998 after a long legislative process. At the time, the academic and policy discussions were based on mere abstract scientific possibilities and imaginary dystopic eugenic futures. Today we are confronted with realistic possibilities for life saving genetic health interventions, that can be made possible provided there is enough incentive to innovation in genetic therapy. Science and technology has progressed considerably in the last 20 years. It will be argued that developments in scientific knowledge and technology are a factor to be taken into consideration in legal interpretation and de lege ferenda proposals.

Ämnesord

SAMHÄLLSVETENSKAP  -- Juridik (hsv//swe)
SOCIAL SCIENCES  -- Law (hsv//eng)

Nyckelord

Patent law
AI patents
Gene editing patents
Stem cell patents
Patent exceptions
Patent eligibility
Private law
Patenträtt
Civilrätt

Publikations- och innehållstyp

kap (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Nordberg, Ana
Gervais, Daniel
Om ämnet
SAMHÄLLSVETENSKAP
SAMHÄLLSVETENSKA ...
och Juridik
Artiklar i publikationen
Fairness, Morali ...
Av lärosätet
Lunds universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy